This approval makes Ozempic the first GLP-1 treatment for patients with both conditions.
Chronic kidney disease is common in people with diabetes.
About one in three adults with diabetes have kidney disease, known asdiabetic kidney disease.
Steve Christo - Corbis / Getty Images
The expanded approval was based on findings from a Phase 3 trial that lasted 3.4 years.
The participants also had slower rates of kidney decline and were less likely to die from heart problems.
It’s unclear if Ozempic can treat kidney disease in patients without diabetes.
The benefit may have come from the secondary effects of weight loss and improved metabolic control.
Centers for Disease Control and Prevention.Chronic Kidney Disease.
2024;391(2):109-121. doi:10.1056/NEJMoa2403347
